Night Squared LP Takes $9.47 Million Position in The Clorox Company $CLX

Night Squared LP purchased a new stake in The Clorox Company (NYSE:CLX) in the fourth quarter, HoldingsChannel reports. The firm purchased 93,958 shares of the company’s stock, valued at approximately $9,474,000. Clorox makes up approximately 2.7% of Night Squared LP’s investment portfolio, making the stock its 5th largest position.

A number of other hedge funds have also made changes to their positions in the company. State Street Corp increased its position in shares of Clorox by 3.5% in the third quarter. State Street Corp now owns 8,434,277 shares of the company’s stock valued at $1,039,946,000 after buying an additional 282,794 shares in the last quarter. Invesco Ltd. increased its position in shares of Clorox by 23.1% in the third quarter. Invesco Ltd. now owns 3,995,590 shares of the company’s stock valued at $492,656,000 after buying an additional 750,415 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Clorox by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 3,172,233 shares of the company’s stock valued at $318,613,000 after buying an additional 10,060 shares in the last quarter. Van ECK Associates Corp increased its position in shares of Clorox by 15.7% in the fourth quarter. Van ECK Associates Corp now owns 3,136,405 shares of the company’s stock valued at $316,244,000 after buying an additional 426,433 shares in the last quarter. Finally, Two Sigma Investments LP increased its position in shares of Clorox by 33.8% in the third quarter. Two Sigma Investments LP now owns 1,740,175 shares of the company’s stock valued at $214,564,000 after buying an additional 439,797 shares in the last quarter. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Clorox Stock Up 1.6%

CLX opened at $97.52 on Wednesday. The company has a quick ratio of 0.65, a current ratio of 0.84 and a debt-to-equity ratio of 27.03. The firm has a market cap of $11.79 billion, a P/E ratio of 15.83, a PEG ratio of 0.50 and a beta of 0.56. The Clorox Company has a 52 week low of $84.70 and a 52 week high of $132.03. The business’s fifty day simple moving average is $96.26 and its 200 day simple moving average is $105.05.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Thursday, April 30th. The company reported $1.64 EPS for the quarter, beating analysts’ consensus estimates of $1.55 by $0.09. The business had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.67 billion. Clorox had a return on equity of 443.64% and a net margin of 11.18%.The business’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter last year, the company earned $1.45 earnings per share. Clorox has set its FY 2026 guidance at 5.450-5.650 EPS. As a group, equities research analysts anticipate that The Clorox Company will post 5.61 EPS for the current fiscal year.

Insider Transactions at Clorox

In other Clorox news, Director Pierre R. Breber purchased 5,000 shares of the firm’s stock in a transaction on Tuesday, May 5th. The shares were purchased at an average cost of $85.82 per share, with a total value of $429,100.00. Following the purchase, the director owned 18,000 shares in the company, valued at approximately $1,544,760. This represents a 38.46% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.63% of the company’s stock.

Analyst Upgrades and Downgrades

CLX has been the subject of a number of research analyst reports. Morgan Stanley dropped their price target on Clorox from $110.00 to $97.00 and set an “equal weight” rating for the company in a research report on Friday, May 1st. BNP Paribas Exane decreased their price objective on Clorox from $128.00 to $97.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 12th. UBS Group decreased their price objective on Clorox from $110.00 to $96.00 and set a “neutral” rating on the stock in a research note on Friday, May 1st. Weiss Ratings raised Clorox from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, April 13th. Finally, Citigroup decreased their price objective on Clorox from $110.00 to $97.00 and set a “neutral” rating on the stock in a research note on Friday, May 1st. One analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat.com, Clorox has an average rating of “Reduce” and a consensus target price of $103.40.

Clorox Profile

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.